Geretsegger C, Fartacek R
Department of Psychiatry I, Landesnervenklinik Salzburg, Austria.
Eur Neuropsychopharmacol. 1998 Aug;8(3):191-4. doi: 10.1016/s0924-977x(97)00057-6.
In an open study, nineteen in-patients fulfilling the criteria for an alcohol withdrawal syndrome (DSM-III-R 291.80) were treated with intravenous caroverine (400 mg/12 h). Caroverine is a class B calcium-channel-blocker and antiglutamatergic agent with significant effects on the brain function. Caroverine exhibits competitive AMPA antagonism, and at higher concentrations, non-competitive NMDA antagonism. All rating scales showed a significant improvement from the start of the treatment throughout the whole study period (CIAW-Ar: P=0.0000; NGI 1: P=0.0000, NGI 2: P=0.0304; CGI 1: P=0.0000, CGI 2: P=0.0208, CGI 3: P=0.0003). The heart rate also stabilised from 111/min before treatment to 81/min after 12 h (P=0.0000). Caroverine was well tolerated, showed no sedative side effects, and no epileptic seizures were observed.
在一项开放性研究中，19名符合酒精戒断综合征标准（DSM-III-R 291.80）的住院患者接受了静脉注射卡罗维林（400毫克/12小时）治疗。卡罗维林是一种B类钙通道阻滞剂和抗谷氨酸能药物，对脑功能有显著影响。卡罗维林表现出竞争性AMPA拮抗作用，在较高浓度时表现出非竞争性NMDA拮抗作用。所有评定量表在整个研究期间从治疗开始时均显示出显著改善（CIAW-Ar：P=0.0000；NGI 1：P=0.0000，NGI 2：P=0.0304；CGI 1：P=0.0000，CGI 2：P=0.0208，CGI 3：P=0.0003）。心率也从治疗前的111次/分钟稳定到12小时后的81次/分钟（P=0.0000）。卡罗维林耐受性良好，未出现镇静副作用，也未观察到癫痫发作。
